Enanta Pharmaceuticals, Inc. (ENTA) said the final data for EDP-514 from phase 1b studies in viremic and NUC-suppressed chronic HBV patients, gives the company continued confidence in EDP-514 as a potential treatment for class II hepatitis B virus. At 800 mg, EDP-514 continued to show that it is safe and well-tolerated up to 28 days when dosed alone or in combination with NUC, in the NUC-suppressed patients. EDP-514 has strong antiviral activity across all dose groups, the company noted.
"These data are supportive of a once-daily oral dosing regimen that could provide a foundation for a combination therapy approach to achieve functional cures for chronic HBV patients," said Jay Luly, President and CEO of Enanta Pharma.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.